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bone pain
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Milnesa, Herbert H. Seltzmanc, Igor Spigelmand, Todd W. Vanderaha,*
Abstract
Manymalignant cancers, including breast cancer, have a propensity to invade bones, leading to excruciating bone pain. Opioids are
the primary analgesics used to alleviate this cancer-induced bone pain (CIBP) but are associated with numerous severe side effects,
including enhanced bone degradation, which significantly impairs patients’ quality of life. By contrast, agonists activating only
peripheral CB1 receptors (CB1Rs) have been shown to effectively alleviate multiple chronic pain conditions with limited side effects,
yet no studies have evaluated their role(s) in CIBP. Here, we demonstrate for the first time that a peripherally selective CB1R agonist
can effectively suppress CIBP. Our studies using a syngeneic murine model of CIBP show that both acute and sustained
administration of a peripherally restricted CB1R agonist, 4-{2-[-(1E)-1[(4-propylnaphthalen-1-yl)methylidene]-1H-inden-3-yl]ethyl}
morpholine (PrNMI), significantly alleviated spontaneous pain behaviors in the animals. This analgesic effect by PrNMI can be
reversed by a systemic administration but not spinal injection of SR141716, a selective CB1R antagonist. In addition, the cancer-
induced bone loss in the animals was not exacerbated by a repeated administration of PrNMI. Furthermore, catalepsy and
hypothermia, the common side effects induced by cannabinoids, were measured at the supratherapeutic doses of PrNMI tested.
PrNMI induced mild sedation, yet no anxiety or a decrease in limb movements was detected. Overall, our studies demonstrate that
CIBP can be effectively managed by using a peripherally restricted CB1R agonist, PrNMI, without inducing dose-limiting central side
effects. Thus, targeting peripheral CB1Rs could be an alternative therapeutic strategy for the treatment of CIBP.
Keywords: Cannabinoids, Cannabinoid receptor 1, Peripherally restricted agonist, PrNMI, Analgesic, Cancer, Pain, Chronic,
Bone loss, Side effects
1. Introduction
Cancer-induced bone pain (CIBP) is experienced by over 30% of
cancer patients with bone metastases8,20 and is considered one
of the most difficult pain conditions to treat.27 Current manage-
ment of CIBP follows the World Health Organization analgesic
ladder recommending opioids for moderate to severe pain.66
However, opioid therapy is not always sufficient in controlling
pain7 and is associated with several dose-limiting side effects
contributing to their inadequate pain relief.46 In addition, opioids
for cancer pain are related to a substance diversion that
contributes to the growing opioid epidemic and drug-related
deaths.6,33 Recent studies in both humans12,19,53 and animals32
indicate that opioids may exacerbate cancer-induced bone
degradation, which counteracts the effects of antiosteolytic
therapies and CIBP management.24,43,57,65 There are also
reports showing that sustained opioids promote cancer pro-
liferation and migration,21,34,40,68 which impedes antitumor
therapy and largely impairs patients’ quality of life. Therefore,
novel analgesics are urgently needed for patients with CIBP.
Recently, cannabinoids have emerged as attractive alterna-
tives for the treatment of both chronic cancer and noncancer
pain.29,31,42,61,62 Cannabinoid receptor agonists have also been
shown to improve bone integrity by regulating the activities of
osteoblasts and osteoclasts,41,60 which is beneficial for the
treatment of CIBP. However, the effectiveness of cannabinoids is
largely limited by their psychotropic effects through the activation
of CB1 receptors (CB1Rs) in the central nervous system
(CNS).16,42 In addition to their CNS expression, cannabinoid
receptors have a wide distribution in peripheral tissues.3,58 The
activation of peripheral cannabinoid receptors exhibits a signifi-
cant inhibition against different chronic pain condi-
tions,4,22,28,38,48,49 including bone cancer pain.11,29,30
Importantly, Agarwal et al.2 discovered that cannabinoid-
induced analgesia is primarily mediated through the activation
of peripheral CB1Rs. Also, some studies identified an increased
expression of CB1Rs in the peripheral tissues under pathological
conditions,4,56 which results in enhanced potency and efficacy of
exogenously applied cannabinoids in the treatment of pain.44
Based on these studies, a potential strategy to dissociate
cannabinoid-mediated analgesia from those psychotropic effects
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is to target peripheral CB1 receptors. Currently, several
peripherally selective CB1 agonists have been developed and
produced robust analgesic effects on chronic pain conditions
with reduced CNS-mediated adverse effects.1,13,52,67 Yet, no
studies have investigated the efficacy of peripherally selective
CB1R agonists in the treatment of established CIBP.
In this study, we investigated the efficacy and mechanism of
a peripherally restricted CB1R agonist, PrNMI,52 in attenuating
spontaneous pain by using a preclinical CIBP model. In
addition, we also evaluated the potential CNS-mediated side
effects induced by this peripherally restricted CB1R agonist.
Our data suggest that PrNMI produces robust analgesic
effects with a decreased CNS-mediated adverse-effect pro-
file, which may provide a valuable alternative for patients with
CIBP.
2. Materials and methods
2.1. In vitro
2.1.1. Cell culture
Murine mammary tumor line, 66.1, was a kind gift from Dr. Amy
M. Fulton.63 66.1 cells were cultured in Eagle’s minimum
essential medium (MEM) with 10% fetal bovine serum, 100 IU21
penicillin, and 100 mg/mL streptomycin, and then housed at 37˚C
and 5% CO2. For all assays, cells were counted using a gridded
hemocytometer (Hausser Scientific, Horsham, PA).
2.1.2. XTT assay
XTT cell viability assay (ATCC, Manassas, VA) was performed
according to the manufacturer’s instructions. Briefly, 66.1 breast
cancer cells were plated into a 96-well plate at a density of 1 3
104 per well and allowed to grow for 24 hours. Cells were then
treated with different concentrations of PrNMI (1 nM-1 mM) or
vehicle for another 24 hours. After treatment, cells were
incubated with activated-XTT solution for 2 hours, and read at
475 and 660 nm using a plate reader.
2.1.3. Western blot analysis
66.1 cells were lysed in the Pierce radioimmunoprecipitation
assay buffer (Thermo Scientific, Rockford, IL) with protease
inhibitor cocktail (Sigma-Aldrich, St. Louis, MO) through ultra-
sonication. Whole cell lysates were resolved on 10% SDS-
polyacrylamide gels (Criterion TGX; Bio-Rad, Hercules, CA) and
transferred to a polyvinylidene difluoride membrane (Bio-Rad).
Polyvinylidene difluoride membrane was blocked with 5% bovine
serum albumin in Tris-buffered saline containing 0.5% (vol/vol)
Tween-20 (TBST) for 1 hour at room temperature, and then
incubated with rabbit polyclonal anti-CB1R (ab23703; Abcam,
Cambridge, MA, 1:3000 dilution) or mouse monoclonal anti–b-
actin (ab8226, Abcam; 1:10,000) diluted in TBST containing 3%
bovine serum albumin overnight at 4˚C. After washing with TBST,
the membrane was incubated with appropriate secondary
antibodies—HRP-linked anti-rabbit IgG (7074; Cell Signaling,
Danvers, MA, 1:10,000 dilution) or HRP-linked anti-mouse IgG
(7076, Cell Signaling; 1:30,000 dilution) for 1 hour at room
temperature. Membrane was again washed and developed using
Clarity Western ECL Substrate (Bio-Rad). Bands were detected
using GeneMate Blue Lite Autorad films (BioExpress, Kaysville,
UT) and quantitated using ImageJ software (Wayne Rasband,
Research Services Branch, NIMH, Bethesda, MD). All data were
normalized to b-actin in each lane.
2.2. In vivo
2.2.1. Animals
All procedures were approved by the University of Arizona Animal
Care and Use Committee and conform to the Guidelines by the
National Institutes of Health and the International Association for
the Study of Pain. Adult female BALB/cAnNHsd mice (18-20 g;
Harlan, Indianapolis, IN) were maintained in a climate-controlled
room on a 12-hour light–dark cycle and allowed food and water
ad libitum. Animals weremonitored on days 0, 7, 10, and 14 of the
study for clinical signs of rapid weight loss and signs of distress.
2.2.2. Intramedullary implantation of 66.1 cells
To establishCIBP inmice using a syngenicmodel,54 an arthrotomy
was performed as previously described.15 Briefly, mice were
anesthetized with 80 mg/kg ketamine 1 12 mg/kg xylazine (in 10
mL/kg, intraperitoneal [i.p.] injection volume), and the condyles of
the right distal femur were exposed. A hole was drilled at the
intercondylar notch and into the medullary canal to create an initial
core pathway. A placement needle was then inserted to make the
final pathway into the bone. Proper placement of the needle was
confirmed using radiograph (UltraFocus, Faxitron Bioptics,
Tucson, AZ). Next, 8 3 104 66.1 cells in 5 mL of complete MEM
or 5 mL of complete MEM alone (as a control) was injected into the
intramedullary space of the femur, and the injection sites were
sealedwith bone cement.Muscle and skinwere closed in separate
layers with 5-0 Vicryl suture and wound autoclips, respectively. All
mice were monitored for anesthesia during the surgery to ensure
that no whisker movement or toe pinch response was presented.
Gentamicin (8 mg/kg, 10 mL/kg volume, subcutaneously) was
given to all mice after surgery to prevent infection. Staples were
removed 7 days after surgery.
2.2.3. Drug treatment
All drugs injected into the animals are dissolved in a vehicle solution
of 10% dimethyl sulfoxide, 10% Tween-80, and 80% saline for
injection (10 mL/kg, i.p.). Acute studies applied one injection of
PrNMI (0.1, 0.3, 0.6, or 1 mg/kg, i.p.) or vehicle. Chronic studies
consisted of once-daily injection of PrNMI (0.6 mg/kg, i.p., every
day [q.d.], days 7-14) or vehicle after femoral inoculation. Separate
sets of animals were treated with selective CB1R antagonist
SR141716 (RTI International, Research Triangle Park, NC) or
CB2R antagonist SR144528 (Tocris, Bristol, United Kingdom) {1
mg/kg, i.p., q.d., 10minutes before PrNMI or 5mg per 5mL (lumbar
puncture [l.p.]), day 14, 30 minutes before the behavioral testing}.
2.2.4. Acute and chronic behavioral testing of spontaneous
pain
Spontaneous pain-related behaviors, flinching and guarding,
were recorded as previously described.15 Flinching was charac-
terized by the lifting and rapid flexing of the ipsilateral hind paw not
associated with walking or other movements. Guarding was
characterized by fully retracting the ipsilateral hind paw under the
torso. These 2 behaviors were observed for 2 minutes during
a resting state after a 30-minute acclimation period. The number
of flinches and the time the hind paw was retracted during the 2-
minute period were recorded. Both flinching and guarding of the
cancer-bearing limb are best described as measurements of
ongoing pain that is reflective in patients with bone cancer who
protect affected limbs.37,51 Guarding and spontaneous flinching
are behaviors observed in which there is, no to very little, contact
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with a ground surface and becomes more progressive with time
(days after femur inoculation).
2.2.4.1. Acute behavioral testing
Baseline behaviors of spontaneous pain were recorded 7 days
after surgery. Mice were then separated into treatment groups
and received a single dose of drug. After drug administration,
mice were tested over a 24-hour time course until their pain
behaviors returned to baseline.
2.2.4.2. Chronic behavioral testing
Spontaneous pain behaviors were assessed before surgery
(baseline). Mice then received treatment at the same time of each
day during day 7 to 14. Spontaneous pain behaviors were
measured 3 hours after treatment on days 7, 10, and 14, based
on the time of peak effect determined by the acute studies.
2.2.5. Radiography
A digital Faxitron machine (UltraFocus; Faxitron Bioptics) was used
to acquire radiographs of mice anesthetized with ketamine/xylazine
before surgery and day 14 after surgery. Bone loss was rated by 3
blindedobservers trained in scoring animal radiographsaccording to
the following scale: 05 normal bone, 15 1 to 3 radiographic lesions
indicating bone loss, 25 4 to 6 radiographic lesions indicating bone
loss, 3 5 full-thickness unicortical bone loss indicating unicortical
bone fracture, and 45 full-thickness bicortical bone loss indicating
bicortical bone fracture. Observer scores for each bone on day 14
were averaged.
2.2.6. Open-field testing
An open-field test was used to investigate the potential sedative
effect of PrNMI. The open-field arena (333 283 33 cm) is a white
box with an open top and a black floor. A rectangle (16.5314 cm)
was marked in the center of the field. Sessions began by placing
the mouse in the center rectangle and ended after 5 minutes. A
consistent white noise (;55 dB) and a dim lighting (;24 lux) were
applied during the test. The entire session was recorded by
a video camera mounted 1.5 m above the floor. The tracking of
mouse movement was realized by analyzing the testing videos
with an open-source tracking software, EthoWatcher.10
2.2.7. Rotarod
A rotarod test was used to determine the motor effect of PrNMI.
Four days before testing, naivemicewere trained to acclimate to the
rotating rod (LE8505 Rota-Rod; Panlab Harvard Apparatus,
Barcelona, Spain) at a speed of 10 rpm. A maximal cutoff time of
180 secondswasused toprevent exhaustion.On thedayof testing,
mice were baselined and reevaluated 3 hours after treatment.
2.2.8. Rectal temperature testing
Animal rectal temperaturewasmeasuredby using a thermistor probe
(Thermoworks, American Fork, UT) to investigate the hypothermia
induced by PrNMI. On the testing day, the rectal temperature was
measured before treatment and 3 hours after treatment.
2.2.9. Ring immobility testing
As CB1R agonists cause catalepsy in animals,16 a ring immobility
test was used to determine the cataleptic effect of PrNMI, as
described previously.45 Briefly, mice were placed on a horizontal
metal ring (5.5 cm diameter) attached to a ring stand at a height of
16 cm. Each mouse was observed for 5 minutes, and the sum of
time it remained motionless was counted. The criterion for
immobility was the absence of all voluntary movements including
snout and whisker movements, but the movements associated
with breathing were excluded. Immobility is described as the
percentage of the 5-minute period in which the mouse was
motionless.
3. Statistical analysis
Two-way analysis of variance with the Tukeymultiple comparisons
test was used to compare acute and chronic behavioral studies of
spontaneous pain; the Kruskal–Wallis test with the Dunn multiple
comparisons test was used to compare the radiograph results; 1-
way analysis of variance with the Dunn multiple comparisons test
was used to analyze XTT assay, rotarod, open-field testing, rectal
temperature testing, and ring immobility testing. All data are
presented as mean 6 SEM or median 6 interquartile range, and
a value of P , 0.05 was accepted as statistically significant.
Statistical analyses were run, and plots were generated in
GraphPad Prism 7.0 (Graph Pad Inc, San Diego, CA). Power
analyseswereperformedon cumulated data by usingG*Power 3.1
software to estimate the optimal numbers required. The adequate
statistical separation requires a group size of 8 to 12 per individual
behavioral assay to detect differences (80%) between the drugs
and control groups at a , 0.05.
4. Results
4.1. Acute or sustained administration of PrNMI attenuates
cancer-induced bone pain
We assessed the acute antinociceptive effect of PrNMI on
spontaneous pain in the syngeneic murine model of CIBP. In this
model, 66.1 murine breast cancer cells were inoculated into the
right femur of BALB/c mice. Before surgery, no mouse presented
with any spontaneous pain behaviors (Figs. 1A and B), but 7
days after femoral inoculation, mice injected with 66.1 cancer
cells displayed a significant amount of flinching and guarding,
which are behavioral signs of spontaneous pain (Figs. 1A and B).
A single injection of PrNMI (0.1, 0.3, and 0.6 mg/kg, i.p.) resulted
in a significant, time-related reduction of flinching but not
guarding in a dose-dependent manner (Figs. 1A and B). This
suppression of flinching started 1-hour after injection and
persisted for at least 5 hours (Fig. 1A).
Cancer-bearing mice treated with vehicle presented with
spontaneous flinching and guarding starting at day 7 and
increasing through day 14 (Figs. 2A and B). Repeated
administration of PrNMI (0.6 mg/kg, i.p., q.d., from day 7-14)
significantly attenuated both flinching and guarding on days 10
and 14 after surgery when compared with vehicle-treated
cancer-bearing mice (Figs. 2A and B). Pretreatment with
selective CB1R antagonist, SR141716 (1 mg/kg, i.p., q.d., from
day 7-14), suppressed this antinociceptive effect produced by
PrNMI, whereas the administration of a selective CB2R antag-
onist, SR144528 (1 mg/kg, i.p., q.d., from day 7-14), did not
(Figs. 2C and D). To confirm that the antinociceptive effect of
PrNMI occurs by targeting peripheral cannabinoid receptors, we
injected the antagonist (SR141716 or SR144528, 5 mg/5 mL) or
the vehicle spinally into the animals receiving chronic PrNMI. The
results indicate that no significant difference in pain behaviors
was displayed between the antagonist and vehicle groups
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(Figs. 2E and F). Together, these data indicate that the
administration of PrNMI attenuates CIBP by targeting peripheral
CB1Rs.
4.2. Sustained PrNMI does not alter bone integrity in mice
with cancer-induced bone pain
To determine whether the effect of sustained PrNMI on bone
remodeling contributes to PrNMI-induced analgesia, radio-
graphic images of all mice were taken on days 0 and 14 after
surgery (Fig. 3A). Bone loss was rated by 3 blinded observers
according to an established scale (see Materials and methods).
Mice injected with media only displayed a mild bone loss in the
femurs (16 of 20 mice have a score of 1 or less) (Figs. 3A and B).
By contrast, almost all cancer-bearing mice experienced severe
bone loss (21 of 24 mice have a score of 2 or more) (Figs. 3A and
B). Sustained treatment with PrNMI (0.6 mg/kg, i.p., q.d., from
day 7-14 after surgery) did not mitigate or worsen this cancer-
induced bone degradation compared with vehicle group (Figs.
3A and B).
4.3. PrNMI does not alter cancer cell viability in vitro
The 66.1 murine breast cancer cells used in this study were
identified to express CB1Rs (Fig. 4A). To investigate whether
PrNMI alters tumor viability that may indirectly influence sponta-
neous pain, 66.1 breast cancer cells were treated in vitro with
varying concentrations of PrNMI (1 nM-1 mM) or vehicle for 24
hours, and an XTT assay was performed. As compared to
vehicle-treated cells, none of the PrNMI treatments significantly
changed cell viability (Fig. 4B). Overall, these data indicate that
PrNMI at the concentrations tested does not promote nor reduce
cancer cell viability in vitro.
4.4. Central side effects are induced by PrNMI in naive mice
Previous studies suggested that brain-permeant CB1R agonist
administration lead to central adverse consequences including
sedation, motor incoordination, hypothermia, and catalepsy,16,42
which largely limits their value as therapeutic reagents. Here, we
performed open-field, rotarod, core temperature, and ring
immobility tests to determine whether PrNMI produces these
adverse effects. In the open-field test, a single administration of
PrNMI (0.6 mg/kg, i.p.) significantly decreased the distance that
mice traveled within a 5-minute period (Fig. 5A). However, the
tracking patterns, center time, and moving time performed by
these naive mice were not altered (Figs. 5B–D). In addition,
PrNMI (0.6 mg/kg, i.p.) did not reduce the time that naive mice
spent on the rotating rod when compared with vehicle-treated
mice (Fig. 6A). Rectal temperature in naive mice was significantly
decreased when treated with 1 mg/kg PrNMI compared with
vehicle group, a dose 10-fold higher than the approximate ED50
analgesic dose (0.1 mg/kg) (Fig. 6B), yet mice treated with 0.6
mg/kg or lower doses of PrNMI did not show a significant
decrease in their body temperature (Fig. 6B). PrNMI also
produced a significant increase in the time that mice spent
motionless in the ring test whenmicewere treatedwith 0.6mg/kg
or a higher dose of PrNMI (Fig. 6C).
5. Discussion
Cancer-induced bone pain is one of the most common types of
chronic pain in patients with cancer, which presents in more than
30% of the patients with cancer who have bone metastasis.8,20
Currently, opioids are the primary medications for CIBP.66
However, opioids are not always sufficient in pain management
and are associated with severe adverse effects and contribute to
the growing opioid epidemic and drug-related
deaths.6,7,12,19,32,33,46,53 Cannabinoids are considered a promis-
ing alternative analgesic to opioids, having demonstrated potent
antiallodynic effects in multiple chronic pain conditions, including
CIBP.17,23,29,31,42,61,62 Nevertheless, cannabinoids have had
limited success in the clinic because of their central side effects
induced by the activation of CB1Rs in the CNS.16,42 Recent
studies demonstrate that activation of only peripheral cannabi-
noid receptors can produce significant antinociceptive effects on
different chronic pain models.2,11,22,28–30,38,48,49 Consistent with
these studies, the use of peripherally restricted cannabinoids also
exerts profound antiallodynic effects on several neuropathic and
inflammatory pain states.1,13,52,67 Furthermore, limited central
Figure 1. Acute administration of PrNMI attenuates spontaneous pain in a cancer-induced pain model. On day 7 after femoral inoculation with 66.1 breast cancer
cells or cell-free media, animals were treated with PrNMI (0.1, 0.3, or 0.6mg/kg, intraperitoneally [i.p.]) or vehicle (80% saline, 10%DMSO, 10% Tween 80, 10mL/
kg, i.p.), and spontaneous pain behaviors including (A) flinching and (B) guarding were recorded in a 2-minute period at various time points. (A) Spontaneous
flinching was significantly reduced by PrNMI compared with animals that received vehicle. (B) No significant difference was observed in spontaneous guarding
between PrNMI-treated and vehicle-treated cancer-bearing mice. For both flinching and guarding, no significant difference was observed in media-only control
animals between PrNMI-treated and vehicle-treated groups. *P, 0.05, 0.6 mg/kg PrNMI vs vehicle; #P, 0.05, 0.3 mg/kg PrNMI vs vehicle;1P, 0.05, 0.1 mg/
kg PrNMI vs vehicle. Values represent the mean 6 SEM, n 5 10 to 12 per group.
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side effects were induced by these peripherally restricted
agonists compared with typical cannabinoids.1,13,52,67
In this study, we evaluated the analgesic effect of a restricted
selective cannabinoid PrNMI in a murine model of CIBP. Our
results show that both a single injection and repeated adminis-
tration of PrNMI significantly alleviate CIBP-induced spontaneous
pain behaviors, including flinching and guarding. In addition, our
antagonist studies suggest that CB1Rs but not CB2Rs mediate
the analgesic effect of PrNMI inmice. These results are consistent
with our previous finding that PrNMI suppresses mechanical
allodynia in a rat model of neuropathic pain by activating CB1Rs
rather than CB2Rs.52 Spinal application of SR141716A, a selec-
tive CB1R antagonist, failed to block PrNMI analgesia confirming
peripheral selectivity of the compound. Thus, a peripherally
restricted cannabinoid is sufficient to attenuate CIBP in mice.
The exact mechanisms by which peripherally restricted CB1R
agonists produce their antiallodynic effects on CIBP are poorly
understood. A probable mechanism is the suppression of
nociceptor activity within the tumor–bone microenvironment.
Cancer metastasis to the bone results in the damage and
sprouting of primary afferent fibers, as well as inflammatory
responses in the tumor–bone microenvironment, which activates
nociceptive neurons and subsequently produces pain.14,36
CB1Rs are known to be expressed on the peripheral terminals
of primary afferents3 and are upregulated under multiple
pathological conditions.4,56 Previous studies showed that pe-
ripheral application of CB1R agonists or increase in endocanna-
binoids greatly attenuated both chronic cancer and noncancer
pain locally, as well as decreased spontaneous activity and
sensitization of nociceptors,22,28–31,48,49 indicating that the
Figure 2. Sustained administration of PrNMI attenuates spontaneous pain in a cancer-induced pain model through actions at peripheral CB1Rs. On day 7 after
femoral inoculation, animals demonstrated bone cancer-induced (A) flinching and (B) guarding. PrNMI (0.6 mg/kg, intraperitoneally [i.p.]) or vehicle (80% saline,
10%DMSO, 10%Tween 80, 10mL/kg, i.p.) was administered after behavioral measurements on day 7 and continued to day 14 (q.d.). Spontaneous flinching and
guarding were recorded at 3-hour time points after treatment on days 7, 10, and 14. (A and B) Spontaneous flinching and guarding were significantly reduced by
PrNMI compared with animals that received vehicle on days 10 and 14. For both flinching and guarding, no significant difference was observed in media-only
control animals between PrNMI-treated and vehicle-treated groups. (C and D) The attenuation of bone cancer-induced flinching and guarding by PrNMI on day 14
was inhibited by pretreatment with the selective CB1R antagonist SR141716 (1mg/kg, i.p., q.d., 10minutes before PrNMI) but not inhibited by the selective CB2R
antagonist SR144528 (1 mg/kg, i.p., q.d., 10 minutes before PrNMI). (E and F) Spinal administration of either SR141716 or SR144528 (5 mg per 5 mL, 2.5 hours
after PrNMI treatment) did not inhibit the antinociceptive effect of PrNMI suggesting actions at peripheral receptors. *P, 0.05, **P, 0.01, ***P, 0.001, and ****P
, 0.0001; n.s., not significant; values represent the mean 6 SEM; n 5 8 to 12 per group.
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peripheral terminals of nociceptors are a critical site of
cannabinoid-induced analgesia. By using a conditional peripheral
CB1R knockout mouse strain, Agarwal et al.2 nearly completely
blocked the antinociceptive effect of systemically administered
cannabinoids, thus demonstrating that cannabinoid-induced
analgesia primarily occurs through the CB1R receptors distrib-
uted on peripheral terminals of nociceptors. Our present study
demonstrates that the activation of peripheral CB1Rs can
effectively suppress CIBP in a mouse model of CIBP because
the selective CB1R antagonist given spinally did not block the
PrNMI analgesic effect, whereas systemic administration signif-
icantly attenuated the effects. Based on these studies, it is likely
that peripherally selective agonists activate CB1Rs on peripheral
nociceptors, thus reducing CIBP. Further study would investigate
whether the knockout of CB1Rs on the nociceptors within the
tumor–bone microenvironment may prevent the antinociceptive
effect of peripherally restricted CB1R agonists.
We also investigated the effect of PrNMI on bone remodeling in
our murine CIBPmodel because cancer-induced bone fracture is
one of themajor components contributing to bone cancer pain.39
In a normal healthy bone, bonemass ismaintained by the balance
between the activities of osteoblasts, the bone forming cells, and
osteoclasts, the bone resorbing cells.5 When cancer cells invade
the bone, the balance is disrupted, eventually leading to net bone
loss.9 Cannabinoid receptors are involved in this modulation of
bone remodeling. CB1Rs are mainly expressed on the nerve
fibers innervating bone.59,60 Osteoblasts and osteoclasts also
express CB1Rs, but at low levels.26,50 By contrast, CB2Rs are
mainly expressed by osteoclasts, osteoblasts, and osteo-
cytes.25,41 CB2R activation was identified to produce antiosteo-
lytic effects in different animal models of bone loss. Studies by
Lozano-Ondoua et al.35 demonstrated that CB2R agonism can
result in a significant decrease in cancer-induced bone loss by
directly inhibiting osteoclast activity, playing a role in the CB2
mechanism of antinociception. Ofek et al. and Sophocleous et al.
found that the activation of CB2Rs can inhibit age-related and
ovariectomy-induced osteoporosis by promoting osteoblast
differentiation and suppressing osteoclast function.41,55 How-
ever, the functional role of CB1Rs in bone remodeling is still
controversial. Previous studies by Tam et al.60 suggest that the
CB1Rs present on skeletal sympathetic nerve terminals promote
bone formation by suppressing norepinephrine release. Idris
et al.25 reported that genetic deletion of CB1Rs prevents
ovariectomy-induced bone loss by inhibiting the activity of
osteoclasts. Our chronic studies show that the peripherally
restricted CB1R agonist PrNMI does not significantly reduce
Figure 3. Sustained administration of PrNMI does not alter bone integrity. Animal femurs were inoculated with 66.1 breast cancer cells or cell-free media after
baseline (presurgery) behavioral measurements. PrNMI (0.6 mg/kg, intraperitoneally [i.p.]) or vehicle (80% saline, 10%DMSO, 10% Tween 80, 10mL/kg, i.p.) was
administered on postsurgery days 7 to 14 (q.d.). On day 14, live radiographs were taken. Bone lesions are indicated by white arrows. Bone loss was rated
according to an established scale (see Materials and methods). (A and B) Cancer-bearing mice had more severe bone loss than shammice. PrNMI treatment did
not significantly change cancer-induced bone loss. **P , 0.01; n.s., not significant; values represent the median 6 interquartile range; n 5 10 to 12 per group.
Figure 4. PrNMI does not alter the viability of 66.1 breast tumor cells in vitro. (A) CB1 receptors are expressed on 66.1 breast cancer cells. (B) 66.1 breast cancer
cells do not have a change in their viability when treated with PrNMI. 66.1 breast cancer cells were plated into a 96-well plate at a density of 1 3 104 per well.
Twenty-four hours later, cells were treated with different concentrations of PrNMI. After a 24-hour incubation, the cell viability was tested using XTT assay. Values
represent the mean 6 SEM; n 5 12 per group.
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bone loss. Differences may be explained by the chronicity of
receptor inactivation in CB1R-KO vs a 7-day agonist activity in our
studies. Furthermore, differencesmay be due tomouse strains or
the construct used for genetic mutation.5
The psychotropic actions mediated by central CB1Rs repre-
sent the most troubling side effects that limit the clinical use of
CB1R agonists.16,42 Catalepsy, hypothermia, motor incoordina-
tion, and sedation are the classic indicators of central CB1Rs
Figure 5. PrNMI administration does not produce anxiety nor a decrease in ambulation, yet results in a decrease in the distance traveled in the open-field test.
Three hours before the open-field test, mice were injected with either PrNMI (0.3, 0.6 or 1mg/kg, intraperitoneally) or vehicle (80% saline, 10%DMSO, 10%Tween
80, 10mL/kg). (A) Mice given an acute administration of PrNMI did not show a significant difference in the (A) tracking patterns, (C) center time (the time the mouse
stepped both front limbs in the center rectangle), and (D) moving time (the time the mouse moved at least 1 hind limb). However, significant difference was
observed in the (B) travel distance between PrNMI-treated and vehicle-treated mice. *P, 0.05, **P, 0.01; values represent the mean6 SEM; n5 12 per group.
Figure 6. PrNMI administration at analgesic doses for CIBP does not impair motor function or hypothermia. (A) PrNMI does not impair animal locomotion at all
testing doses. (B) Hypothermia was induced by PrNMI at the highest dose tested (1 mg/kg). (C) Catalepsy was seen only at the highest dose tested in the cancer-
induced flinching (0.6 mg/kg) as well as at the higher dose of 1 mg/kg. No catalepsy was measured at the dose of 0.3 mg/kg. In all 3 tests, mice were
intraperitoneally injected with either PrNMI (0.3, 0.6, or 1 mg/kg) or vehicle (80% saline, 10% DMSO, 10% Tween 80, 10 mL/kg). All tests were performed before
treatment and 3 hours after injection. *P, 0.05, ****P, 0.0001; values represent themean6SEM; n5 10 to 12 per group; CIBP, cancer-induced bone pain; n.s.,
not significant.
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activation.16 Here, we used the open-field test, rotarod test, rectal
temperature test, and ring immobility test to determine the CNS
actions of PrNMI. Our data indicate that PrNMI does not induce
motor incoordination in naivemice. In addition, hypothermia is not
seen at any of the antinociceptive doses, but is detected at a 10-
fold higher dose than the approximate analgesic ED50 dose (0.1
mg/kg). Catalepsy was not present at a dose of 0.3 mg/kg but
was moderately induced by PrNMI at 0.6 and 1.0 mg/kg as
compared to our previous publication using a centrally acting
CB1 agonist, WIN55,212-2.38 Interestingly, the open-field test
shows a decrease in total travel distance, but no differences were
observed in tracking patterns, center time, or moving time.
Although there are no published studies that have previously
reported such findings, the idea that animals may have a re-
duction in overall travel distance but no significant change in
activity on the rotarod, center time, and most importantly moving
time might suggest that the peripherally restricted cannabinoids
may cause animals to move more in a stationary place. A review
by Walsh and Cummins64 described that decreases in ambula-
tion in an open-field test typically indicates locomotor function
and emotionality (anxiety/sedation); yet, our lack of an effect using
rotarod and the no change in center time suggest no locomotor/
sedation or anxiety activity, respectively. Further studies will need
to confirm whether a peripherally restricted cannabinoid may
result in an overall decrease in distance traveled and/or other
changes in motor performance such as increased grooming. Our
previous pharmacokinetic findings in rats demonstrated minimal
CNS access of PrNMI after systemic administration, particularly
compared with other reported peripherally restricted CB1R
agonists, as well as typical cannabinoids.1,13,52,67 Overall, PrNMI
produces limited central actions yet full antinociceptive efficacy in
inhibiting bone cancer pain.
The leading reason that CIBP remains a significant health
problem today is the limited efficacy of analgesics available to
treat this pain without impairing the patients’ quality of life and
the bone health of the patients. Opioid therapy is the primary
treatment of moderate to severe bone cancer pain after cancer
metastasis to bone.66 Although opioids are very effective
analgesics, they cause numerous unwanted side effects that
limit the dose used. Recent studies by our group demonstrate
that chronicmorphine accelerates bone degradation in amurine
model of sarcoma-induced bone loss.32 In addition, opioid
analgesics cause a variety of psychotropic and life-threatening
side effects, including somnolence, agitation, dizziness, cogni-
tive impairment, hyperesthesia, and respiratory depression.47
As a result, the administration of opioids for CIBP significantly
impairs the ability of patients to partake in daily events and
effectively engage with their family and friends reducing their
overall quality of life. Recently, we have shown that the
combination of analgesic therapies, CB2 agonist and a mu
opioid, for chronic pain can synergistically decrease the pain
behaviors while also significantly reduce unwanted effects of
both drugs.18 In this study, we identified a peripherally restricted
CB1R agonist as a promising alternative to the treatment of
CIBP. Our results indicate that PrNMI can exert a profound
analgesic effect on bone cancer pain and should be further
tested in the presence of additional analgesics such as a CB2
agonist or a nonsteroidal anti-inflammatory drug for cancer-
induced pain. Importantly, PrNMI did not exacerbate cancer-
induced bone destruction, did not enhance cancer proliferation,
and produced no severe side effects at therapeutic doses.
Therefore, the use of peripherally restricted CB1R agonists in
the treatment of CIBP is a highly favorable and safe alternative to
current clinical therapy.
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